Scienture Holdings, Inc. (SCNX) - Total Assets
Based on the latest financial reports, Scienture Holdings, Inc. (SCNX) holds total assets worth $87.73 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Scienture Holdings, Inc. - Total Assets Trend (2006–2025)
This chart illustrates how Scienture Holdings, Inc.'s total assets have evolved over time, based on quarterly financial data. Also see Scienture Holdings, Inc. stock valuation for the company's overall valuation and market capitalisation.
Scienture Holdings, Inc. - Asset Composition Analysis
Current Asset Composition (December 2025)
Scienture Holdings, Inc.'s total assets of $87.73 Million consist of 9.4% current assets and 90.6% non-current assets. Review Scienture Holdings, Inc. balance sheet liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 7.9% |
| Accounts Receivable | $731.33K | 0.9% |
| Inventory | $213.41K | 0.3% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $70.97 Million | 84.3% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2006–2025)
This chart illustrates how Scienture Holdings, Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See latest Scienture Holdings, Inc. stock price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Scienture Holdings, Inc.'s current assets represent 9.4% of total assets in 2025, a decrease from 100.0% in 2006.
- Cash Position: Cash and equivalents constituted 7.9% of total assets in 2025, down from 100.0% in 2006.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 84.0% of total assets, an increase from 0.0% in 2006.
- Asset Diversification: The largest asset category is intangible assets at 84.3% of total assets.
Scienture Holdings, Inc. Competitors by Total Assets
Key competitors of Scienture Holdings, Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Raia Drogasil S.A
SA:RADL3
|
Brazil | R$25.13 Billion |
|
Luyan Pharma Co Ltd
SHE:002788
|
China | CN¥13.34 Billion |
|
Oriola-KD Oyj B
HE:OKDBV
|
Finland | €963.50 Million |
|
Empreendimentos Pague Menos S.A
SA:PGMN3
|
Brazil | R$9.81 Billion |
|
d1000 Varejo Farma Participações S.A
SA:DMVF3
|
Brazil | R$1.95 Billion |
|
High Tide Inc
V:HITI
|
Canada | CA$347.87 Million |
|
Yifeng Pharmacy
SHG:603939
|
China | CN¥26.07 Billion |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233
|
China | CN¥26.83 Billion |
Scienture Holdings, Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.04 | 0.11 | 7.92 |
| Quick Ratio | 2.97 | 0.11 | 7.78 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $6.18 Million | $-6.83 Million | $4.53 Million |
Scienture Holdings, Inc. - Advanced Valuation Insights
This section examines the relationship between Scienture Holdings, Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.23 |
| Latest Market Cap to Assets Ratio | 0.17 |
| Asset Growth Rate (YoY) | -19.7% |
| Total Assets | $84.18 Million |
| Market Capitalization | $13.92 Million USD |
Valuation Analysis
Below Book Valuation: The market values Scienture Holdings, Inc.'s assets below their book value (0.17x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Scienture Holdings, Inc.'s assets decreased by 19.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Scienture Holdings, Inc. (2006–2025)
The table below shows the annual total assets of Scienture Holdings, Inc. from 2006 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $84.18 Million | -19.72% |
| 2024-12-31 | $104.85 Million | +736.63% |
| 2023-12-31 | $12.53 Million | +237.81% |
| 2022-12-31 | $3.71 Million | -35.66% |
| 2021-12-31 | $5.77 Million | -41.12% |
| 2020-12-31 | $9.79 Million | +75.76% |
| 2019-12-31 | $5.57 Million | +150.11% |
| 2018-12-31 | $2.23 Million | +260.76% |
| 2017-12-31 | $617.48K | +83.16% |
| 2016-12-31 | $337.12K | -83.37% |
| 2015-12-31 | $2.03 Million | +65.91% |
| 2014-12-31 | $1.22 Million | +202.60% |
| 2013-12-31 | $403.87K | +240.31% |
| 2012-12-31 | $118.68K | +1191.92% |
| 2011-12-31 | $9.19K | -98.66% |
| 2008-12-31 | $687.00K | +38691.64% |
| 2007-12-31 | $1.77K | -86.56% |
| 2006-12-31 | $13.17K | -- |
About Scienture Holdings, Inc.
Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The company develops SCN-102, an oral liquid formulation of losartan potassium that is in phase 1 for the treatment of hypertension, diabetic nephropathy, and reduction of the risk of… Read more